Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.42 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8260611 | 0.85 | GRIN2D (0.35) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL12395750 | 0.81 | CCR1 (0.33) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL23561192 | 0.78 | HSD11B1 (0.34) | HSD11B1 | |
| SCHEMBL26935953 | 0.78 | GRIN2D (0.45) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL10205028 | 0.78 | GRIN2D (0.45) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL10033714 | 0.77 | OPRM1 (0.43) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL23419794 | 0.76 | GRIN2D (0.43) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL20781588 | 0.75 | — | — | |
| SCHEMBL117165 | 0.75 | GRIN2D (0.46) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL23432658 | 0.74 | GRIN2D (0.42) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043620-B2 | Benzazole compounds and methods for making and using the compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| WO-2024107763-A1 | N6-ADENOSINE-METHYLTRANSFERASE PROTACS AND METHODS OF USE THEREOF | UNIVERSITY OF ZURICH (CH) | 2024-05-23 | — | — | WO | disclosed |
| EP-4341263-A1 | N6-ADENOSINE-METHYLTRANSFERASE INHIBITORS IN CANCER TREATMENT | Universität Zürich (CH) | 2024-03-27 | — | — | EP | disclosed |
| WO-2023235618-A1 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN | BIOMEA FUSION, INC. (US) | 2023-12-07 | — | — | WO | disclosed |
| US-11834454-B2 | Alkynylphenylbenzamide compounds and applications thereof | SHENZHEN NEWDEL BIOTECH CO., LTD. (CN) | 2023-12-05 | — | — | US | disclosed |
| US-11834454-B2 | Alkynylphenylbenzamide compounds and applications thereof | SHENZHEN NEWDEL BIOTECH CO., LTD. (CN) | 2023-12-05 | — | — | US | disclosed |
| WO-2023222762-A1 | N6-ADENOSINE-METHYLTRANSFERASE PROTACS AND METHODS OF USE THEREOF | UNIVERSITY OF ZURICH (CH) | 2023-11-23 | — | — | WO | disclosed |
| US-11786575-B2 | Endoparasitic depsipeptides | ZOETIS SERVICES LLC (US) | 2023-10-17 | — | — | US | disclosed |
| US-11773068-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773068-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CHEMOCENTRYX, INC. | 2010-09-16 | — | — | US | disclosed |
| US-20100197908-A1 | Pyridazine Derivatives with MCH Antagonistic Activity and Medicaments Comprising These Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-05 | — | — | US | disclosed |
| US-7524862-B2 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-28 | — | — | US | disclosed |
| US-7485641-B2 | Substituted 3-amino-pyrrolidino-4-lactams | PFIZER, INC. (US) | 2009-02-03 | — | — | US | disclosed |
| US-20080255083-A1 | NEW PYRIDONE DERIVATES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-16 | — | — | US | disclosed |
| US-20070299076-A1 | Substituted 3-Amino-Pyrrolidino-4-Lactams | PFIZER INC | 2007-12-27 | — | — | US | disclosed |
| US-20070275964-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | PFIZER, INC. | 2007-11-29 | — | — | US | disclosed |
| US-7268133-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER, INC. PATENT DEPARTMENT (US) | 2007-09-11 | — | — | US | disclosed |
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | ROTH GERALD J | 2007-05-17 | — | — | US | disclosed |
| US-20040214837-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. | 2004-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, GPR119, MCHR2 | GRIN2D 1051/4885GRIN3B 955/4885CHRM2 56/4885 |
| US-11786575-B2 | Endoparasitic depsipeptides | VIP, PREP, NGLY1 | GRIN2D 4587/4885GRIN3B 4154/4885CHRM2 1892/4885 |
| US-12043620-B2 | Benzazole compounds and methods for making and using the compounds | IRAK3, IRAK1, IRAK2 | GRIN2D 3354/4885GRIN3B 1483/4885CHRM2 4481/4885 |
| US-20100197908-A1 | Pyridazine Derivatives with MCH Antagonistic Activity and Medicaments Comprising These Compounds | MCHR1, MCHR2, MC5R | GRIN2D 1746/4885GRIN3B 1756/4885CHRM2 73/4885 |
| US-20080255083-A1 | NEW PYRIDONE DERIVATES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | MCHR1, MCHR2, GPR119 | GRIN2D 1914/4885GRIN3B 1600/4885CHRM2 30/4885 |
| US-20040214837-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | GRIN2D 525/4885GRIN3B 345/4885CHRM2 495/4885 |
| US-11834454-B2 | Alkynylphenylbenzamide compounds and applications thereof | ALK, NTRK1, ERBB2 | GRIN2D 3176/4885GRIN3B 2909/4885CHRM2 4758/4885 |
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CCR2, CCR9, CCR1 | GRIN2D 2203/4885GRIN3B 2818/4885CHRM2 2356/4885 |
| US-20070299076-A1 | Substituted 3-Amino-Pyrrolidino-4-Lactams | PRMT1, PRMT7, PRMT3 | GRIN2D 197/4885GRIN3B 396/4885CHRM2 3941/4885 |
| US-11773068-B2 | KDM1A inhibitors for the treatment of disease | KDM1B, KDM1A, KDM2A | GRIN2D 4053/4885GRIN3B 2938/4885CHRM2 4283/4885 |
| US-20070275964-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR1, CNR2, GPR18 | GRIN2D 540/4885GRIN3B 353/4885CHRM2 523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.